WO2002090304A1 - Solution stable de coenzyme q reduite - Google Patents
Solution stable de coenzyme q reduite Download PDFInfo
- Publication number
- WO2002090304A1 WO2002090304A1 PCT/JP2002/004516 JP0204516W WO02090304A1 WO 2002090304 A1 WO2002090304 A1 WO 2002090304A1 JP 0204516 W JP0204516 W JP 0204516W WO 02090304 A1 WO02090304 A1 WO 02090304A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- coenzyme
- surfactant
- solution according
- reduced coenzyme
- weight
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/34—Separation; Purification; Stabilisation; Use of additives
- C07C41/46—Use of additives, e.g. for stabilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
Definitions
- n an integer of 1 to 12
- FIG. 4 is a graph showing the effect of surfactant concentration on the oxidative stability of reduced coenzyme Q 1Q solution at 23 ° C. using two types of surfactants.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Husbandry (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fats And Perfumes (AREA)
- Fodder In General (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020037013495A KR100617928B1 (ko) | 2001-05-09 | 2002-05-09 | 환원된 조효소 q 의 안정한 용액 |
EP02724742A EP1386905B1 (en) | 2001-05-09 | 2002-05-09 | Stable solution of reduced coenzyme q |
US10/476,083 US20040126367A1 (en) | 2001-05-09 | 2002-05-09 | Stable solution of reduced coenzyme q |
AU2002255329A AU2002255329B2 (en) | 2001-05-09 | 2002-05-09 | Stable solution of reduced coenzyme Q |
CA2442151A CA2442151C (en) | 2001-05-09 | 2002-05-09 | Stable solution of reduced coenzyme q |
US12/328,293 US20090087420A1 (en) | 2001-05-09 | 2008-12-04 | Stable solution of reduced coenzyme q |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001138340 | 2001-05-09 | ||
JP2001-138340 | 2001-05-09 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/328,293 Division US20090087420A1 (en) | 2001-05-09 | 2008-12-04 | Stable solution of reduced coenzyme q |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002090304A1 true WO2002090304A1 (fr) | 2002-11-14 |
Family
ID=18985293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/004516 WO2002090304A1 (fr) | 2001-05-09 | 2002-05-09 | Solution stable de coenzyme q reduite |
Country Status (8)
Country | Link |
---|---|
US (2) | US20040126367A1 (ja) |
EP (1) | EP1386905B1 (ja) |
JP (1) | JP3742602B2 (ja) |
KR (2) | KR100617929B1 (ja) |
CN (1) | CN1263447C (ja) |
AU (1) | AU2002255329B2 (ja) |
CA (1) | CA2442151C (ja) |
WO (1) | WO2002090304A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003032967A1 (en) * | 2001-10-10 | 2003-04-24 | Kaneka Corporation | Method of stabilizing reduced coenzyme q10 |
EP1493437A1 (en) * | 2002-03-20 | 2005-01-05 | Kaneka Corporation | Compositions for diabetes |
EP1690533A1 (en) * | 2003-11-28 | 2006-08-16 | Kaneka Corporation | Composition having liver function protective effect |
US7358402B2 (en) | 2003-09-10 | 2008-04-15 | Kaneka Corporation | Reduced coenzyme Q10 crystal with excellent stability and composition containing said reduced coenzyme Q10 crystal |
US8562975B2 (en) | 2002-01-18 | 2013-10-22 | Kaneka Corporation | Method for stabilizing reduced coenzyme Q10 and composition therefor |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7754205B2 (en) * | 2001-05-10 | 2010-07-13 | Kaneka Corporation | Composition for transmucosal administration containing conenzyme Q as the active ingredient |
TWI349039B (en) | 2001-12-27 | 2011-09-21 | Kaneka Corp | Processes for producing coenzyme q10 |
TW200302055A (en) * | 2002-01-18 | 2003-08-01 | Kaneka Corp | Ubiquinol-enriched fat-containing foods |
US20060251637A1 (en) * | 2003-03-11 | 2006-11-09 | Toshinori Ikehara | Oil-in-water type emulsion containing coenzyme q10 and process for producting the same |
WO2005033054A1 (ja) * | 2003-09-10 | 2005-04-14 | Kaneka Corporation | 安定性に優れた還元型補酵素q10結晶及び還元型補酵素q10結晶を含有する組成物 |
WO2005035477A1 (ja) * | 2003-10-08 | 2005-04-21 | Kaneka Corporation | キノン骨格を有する化合物の安定化方法及び安定化された組成物 |
DK1718283T3 (da) | 2004-01-22 | 2013-04-22 | Univ Miami | Topisk co-enzyme Q10 formuleringer og fremgangsmåder for anvendelse. |
JP5243718B2 (ja) * | 2004-04-09 | 2013-07-24 | 株式会社カネカ | 還元型補酵素q10およびカロチノイド類を含有した組成物 |
US20070259908A1 (en) * | 2004-08-30 | 2007-11-08 | Kaneka Corporation | Mitochondria Activators |
JP2008520563A (ja) | 2004-11-16 | 2008-06-19 | バイオアバイラビリティ,インク. | 栄養学的に使用するための高濃度自己マイクロエマルジョン化コエンザイムq10調製物 |
ES2563929T3 (es) * | 2004-12-24 | 2016-03-16 | Kaneka Corporation | Preparación sólida que comprende coenzima Q10 reducida y proceso para la producción de la misma |
US20060147542A1 (en) * | 2004-12-24 | 2006-07-06 | Tadao Ono | Solid preparation containing reduced coenzyme Q10 and method for producing the same |
JP4877899B2 (ja) * | 2005-01-25 | 2012-02-15 | 学校法人近畿大学 | 薬物徐放出性球状微粒子及びその製造方法 |
US20060198830A1 (en) * | 2005-03-01 | 2006-09-07 | Siddharth Shastri | Ubiquinone composition and a container for its convenient transport and storage |
JPWO2006104153A1 (ja) * | 2005-03-29 | 2008-09-11 | 株式会社カネカ | 血液中の抗酸化活性を高める組成物 |
KR100710639B1 (ko) | 2005-09-21 | 2007-04-24 | 주식회사 씨티씨바이오 | 코엔자임 q10을 함유한 투명한 액상 제제 및 그의제조방법 |
US8506956B2 (en) * | 2005-10-31 | 2013-08-13 | Kaneka Corporation | Method for stabilizing reduced coenzyme Q10 |
WO2007052802A1 (ja) * | 2005-11-07 | 2007-05-10 | Kaneka Corporation | 酸化に対して安定な還元型補酵素q10含有組成物、及び還元型補酵素q10を安定化する方法 |
CN100525753C (zh) * | 2005-11-15 | 2009-08-12 | 董英杰 | 辅酶q10亚微乳注射液及制备方法 |
JP4960004B2 (ja) * | 2006-04-10 | 2012-06-27 | ポーラ化成工業株式会社 | ベシクル分散剤形のユビデカレノン含有化粧料 |
KR100786884B1 (ko) * | 2006-06-27 | 2007-12-20 | 영진약품공업주식회사 | 코엔자임 q10 함유 수용성 조성물 |
CA2662607A1 (en) * | 2006-09-08 | 2008-03-13 | Kaneka Corporation | Composition comprising reduced coenzyme q10 and lysolecithin |
EP2090302A4 (en) * | 2006-11-22 | 2010-01-20 | Asahi Kasei Pharma Corp | DIETETIC SUPPLEMENT, ANTI-FATIGUE AGENT, PHYSICAL ENDURANCE ACTIVATOR, FUNCTIONAL FOOD, OR COSMETIC PRODUCT |
WO2008101344A1 (en) * | 2007-02-22 | 2008-08-28 | Peter Tomlinson | Soluble bioactive lipophilic compounds compositions |
CA2823407C (en) | 2007-03-22 | 2016-10-18 | Berg Pharma Llc | Topical formulations having enhanced bioavailability |
JP5362557B2 (ja) * | 2007-05-30 | 2013-12-11 | 日清ファルマ株式会社 | 植物生長促進剤 |
WO2009126764A1 (en) | 2008-04-11 | 2009-10-15 | Cytotech Labs, Llc | Methods and use of inducing apoptosis in cancer cells |
JP2012526828A (ja) | 2009-05-11 | 2012-11-01 | バーグ バイオシステムズ,エルエルシー | エピメタボリックシフター、多次元細胞内分子、または環境影響因子を使用する代謝性障害の治療方法 |
ES2664793T3 (es) | 2010-03-12 | 2018-04-23 | Berg Llc | Formulaciones intravenosas de coenzima Q10 (CoQ10) y métodos de uso de las mismas |
CN102247301A (zh) * | 2010-05-21 | 2011-11-23 | 上海新都生物科技有限公司 | 还原型辅酶q10的用途及在化妆品中的使用方法 |
WO2012014524A1 (ja) | 2010-07-30 | 2012-02-02 | 株式会社エリナ | 糖代謝改善用組成物及びその組成物を含有する医薬製剤 |
ES2762451T3 (es) | 2011-04-04 | 2020-05-25 | Berg Llc | Tratamiento de tumores del sistema nervioso central con coenzima Q10 |
JP5932993B2 (ja) | 2011-06-17 | 2016-06-08 | バーグ エルエルシー | 吸入可能な医薬組成物 |
CN102793657B (zh) * | 2012-08-22 | 2015-09-16 | 珀莱雅化妆品股份有限公司 | 一种含生物缓冲剂的护肤品 |
EA032775B1 (ru) | 2013-04-08 | 2019-07-31 | Берг Ллк | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 |
WO2014188861A1 (ja) | 2013-05-20 | 2014-11-27 | ユーハ味覚糖株式会社 | ユビキノール高含有ゲル状組成物 |
JP6595478B2 (ja) | 2013-09-04 | 2019-10-23 | バーグ エルエルシー | コエンザイムq10の連続注入によるがんの治療方法 |
RU2605616C1 (ru) * | 2015-11-27 | 2016-12-27 | Закрытое акционерное общество "Институт экспериментальной фармакологии" | Липосомальное средство на основе убихинола и способ его получения |
CN107684561A (zh) * | 2016-08-05 | 2018-02-13 | 上海宣泰生物科技有限公司 | 辅酶q10营养组合物及其应用 |
RU2669374C2 (ru) * | 2016-09-15 | 2018-10-11 | Закрытое акционерное общество "Санкт-Петербургский институт фармации" | Средство на основе биснафтазарина и способ его получения |
DE102019218244A1 (de) * | 2019-11-26 | 2021-05-27 | Beiersdorf Ag | Wirkstoffkombinationen aus Ubichinol und einem oder mehreren Emulgatoren aus der Gruppe der Phosphate und Sulfate sowie kosmetische oder dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend |
JPWO2023120553A1 (ja) * | 2021-12-24 | 2023-06-29 | ||
CN115429758B (zh) * | 2022-09-06 | 2024-05-14 | 厦门金达威生物科技有限公司 | 一种辅酶q10-硫辛酸型磷脂纳米复合胶束及其制备方法和应用 |
CN115531319B (zh) * | 2022-11-25 | 2023-05-05 | 仙乐健康科技股份有限公司 | 一种高稳定性脂质体及其制备方法和用途 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5356315A (en) * | 1976-11-01 | 1978-05-22 | Eisai Co Ltd | Emulsified solution of fat soluble drugs |
EP0069399A2 (en) * | 1981-07-08 | 1983-01-12 | Eisai Co., Ltd. | Pharmaceutical composition containing ubidecarenone containing liposomes |
JPS59161314A (ja) * | 1983-03-06 | 1984-09-12 | Taiho Yakuhin Kogyo Kk | 安定化ユビキノン組成物の製法 |
GB2184355A (en) * | 1985-12-24 | 1987-06-24 | Seuref Ag | Ubiquinone pharmaceutical compositions |
EP0522433A1 (en) * | 1991-07-11 | 1993-01-13 | Inverni Della Beffa S.P.A. | Oral aqueous solutions containing ubidecarenone |
WO1994018948A1 (en) * | 1993-02-23 | 1994-09-01 | The Green Cross Corporation | Process for producing liposome composition |
WO1998007417A1 (fr) * | 1996-08-16 | 1998-02-26 | Kaneka Corporation | Compositions pharmaceutiques contenant de la coenzyme q¿10? |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4824669A (en) * | 1985-04-11 | 1989-04-25 | Board Of Regents, The University Of Texas System | Formulations of coenzyme Q10 for intravenous use |
US5461037A (en) * | 1985-10-15 | 1995-10-24 | Clintec Nutrition Company | Lipid emulsion |
DK487289D0 (da) * | 1989-10-04 | 1989-10-04 | Novo Nordisk As | Omestring af phospholipider |
NZ269847A (en) * | 1993-08-13 | 1996-11-26 | Seikagaku Kogyo Co Ltd | 2-alkylamino-3-morpholino-1-propanol derivative in a composition for neuronal disease treatment |
US6045826A (en) * | 1999-04-02 | 2000-04-04 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
US6740338B1 (en) * | 2000-01-20 | 2004-05-25 | Raj K. Chopra | Reduced form of Cenzyme Q in high bioavailability stable oral dosage form |
US8753675B1 (en) * | 2000-01-20 | 2014-06-17 | Raj K. Chopra | Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications |
US20050070610A1 (en) * | 2000-05-09 | 2005-03-31 | Kenji Fujii | Dermal compositions containing coenzyme q as the active ingredient |
GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
US6441050B1 (en) * | 2000-08-29 | 2002-08-27 | Raj K. Chopra | Palatable oral coenzyme Q liquid |
US7754205B2 (en) * | 2001-05-10 | 2010-07-13 | Kaneka Corporation | Composition for transmucosal administration containing conenzyme Q as the active ingredient |
JP4603192B2 (ja) * | 2001-05-10 | 2010-12-22 | 株式会社カネカ | 毛髪頭皮用組成物 |
TWI329513B (en) * | 2001-10-12 | 2010-09-01 | Kaneka Corp | Use of reduced coenzyme q for lessening oxidative stress |
TW200302056A (en) * | 2002-01-18 | 2003-08-01 | Kaneka Corp | Method for stabilizing reduced coenzyme Q10 and composition therefor |
US7708990B2 (en) * | 2004-03-23 | 2010-05-04 | Kaneka Corporation | Coenzyme Q compositions persisting in blood |
-
2002
- 2002-05-01 JP JP2002129679A patent/JP3742602B2/ja not_active Expired - Fee Related
- 2002-05-09 CA CA2442151A patent/CA2442151C/en not_active Expired - Fee Related
- 2002-05-09 KR KR1020057022537A patent/KR100617929B1/ko active IP Right Grant
- 2002-05-09 AU AU2002255329A patent/AU2002255329B2/en not_active Ceased
- 2002-05-09 CN CNB028073045A patent/CN1263447C/zh not_active Expired - Fee Related
- 2002-05-09 US US10/476,083 patent/US20040126367A1/en not_active Abandoned
- 2002-05-09 KR KR1020037013495A patent/KR100617928B1/ko active IP Right Grant
- 2002-05-09 WO PCT/JP2002/004516 patent/WO2002090304A1/ja active Application Filing
- 2002-05-09 EP EP02724742A patent/EP1386905B1/en not_active Expired - Lifetime
-
2008
- 2008-12-04 US US12/328,293 patent/US20090087420A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5356315A (en) * | 1976-11-01 | 1978-05-22 | Eisai Co Ltd | Emulsified solution of fat soluble drugs |
EP0069399A2 (en) * | 1981-07-08 | 1983-01-12 | Eisai Co., Ltd. | Pharmaceutical composition containing ubidecarenone containing liposomes |
JPS59161314A (ja) * | 1983-03-06 | 1984-09-12 | Taiho Yakuhin Kogyo Kk | 安定化ユビキノン組成物の製法 |
GB2184355A (en) * | 1985-12-24 | 1987-06-24 | Seuref Ag | Ubiquinone pharmaceutical compositions |
EP0522433A1 (en) * | 1991-07-11 | 1993-01-13 | Inverni Della Beffa S.P.A. | Oral aqueous solutions containing ubidecarenone |
WO1994018948A1 (en) * | 1993-02-23 | 1994-09-01 | The Green Cross Corporation | Process for producing liposome composition |
WO1998007417A1 (fr) * | 1996-08-16 | 1998-02-26 | Kaneka Corporation | Compositions pharmaceutiques contenant de la coenzyme q¿10? |
Non-Patent Citations (1)
Title |
---|
See also references of EP1386905A4 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003032967A1 (en) * | 2001-10-10 | 2003-04-24 | Kaneka Corporation | Method of stabilizing reduced coenzyme q10 |
US8703155B2 (en) | 2001-10-10 | 2014-04-22 | Kaneka Corporation | Method of stabilizing reduced coenzyme q10 |
US9532957B2 (en) | 2001-10-10 | 2017-01-03 | Kaneka Corporation | Method of stabilizing reduced coenzyme Q10 |
US8562975B2 (en) | 2002-01-18 | 2013-10-22 | Kaneka Corporation | Method for stabilizing reduced coenzyme Q10 and composition therefor |
EP1493437A1 (en) * | 2002-03-20 | 2005-01-05 | Kaneka Corporation | Compositions for diabetes |
EP1493437A4 (en) * | 2002-03-20 | 2010-08-11 | Kaneka Corp | COMPOSITIONS AGAINST DIABETES |
US7358402B2 (en) | 2003-09-10 | 2008-04-15 | Kaneka Corporation | Reduced coenzyme Q10 crystal with excellent stability and composition containing said reduced coenzyme Q10 crystal |
EP1690533A1 (en) * | 2003-11-28 | 2006-08-16 | Kaneka Corporation | Composition having liver function protective effect |
EP1690533A4 (en) * | 2003-11-28 | 2009-03-11 | Kaneka Corp | COMPOSITION WITH PROTECTIVE EFFECT ON THE LIVER FUNCTION |
Also Published As
Publication number | Publication date |
---|---|
CA2442151A1 (en) | 2002-11-14 |
US20090087420A1 (en) | 2009-04-02 |
CN1263447C (zh) | 2006-07-12 |
EP1386905A4 (en) | 2005-04-27 |
KR20050116402A (ko) | 2005-12-12 |
JP3742602B2 (ja) | 2006-02-08 |
CN1501903A (zh) | 2004-06-02 |
EP1386905A1 (en) | 2004-02-04 |
AU2002255329B2 (en) | 2008-05-08 |
KR100617928B1 (ko) | 2006-08-30 |
JP2003026625A (ja) | 2003-01-29 |
CA2442151C (en) | 2011-10-11 |
US20040126367A1 (en) | 2004-07-01 |
EP1386905B1 (en) | 2012-09-26 |
KR100617929B1 (ko) | 2006-08-30 |
KR20030093318A (ko) | 2003-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002090304A1 (fr) | Solution stable de coenzyme q reduite | |
EP1440962B1 (en) | Stabilized compositions of aqueous reduced coenzyme q solution | |
EP1202719B1 (en) | Anesthetic composition for intravenous injection comprising propofol | |
CN1870982B (zh) | 含还原型辅酶q的组合物 | |
KR101752757B1 (ko) | 상피 성장 인자를 포함하는 소포체 및 이를 포함하는 조성물 | |
CA2534551C (en) | Cosmetic composition to assist transport of oxygen into the skin | |
KR101365252B1 (ko) | 포스파티딜콜린 함유 주사용 조성물 및 이의 제조방법 | |
JP2011219397A (ja) | ピロロキノリンキノンを含むリポソーム | |
EP4112037A1 (en) | Oxygen gas sustained released nano-emulsion composition and method for producing the same | |
TWI334862B (ja) | ||
JP4942354B2 (ja) | 還元型補酵素q水溶化組成物 | |
Musheer et al. | Formulation, Development and Characterization of Effective Niosomal Drug Delivery System for the Treatment of Diabetes Mellitus | |
KR20230000400A (ko) | 산소 기체 서방형 나노 에멀젼 조성물 및 이의 제조방법 | |
US20140335166A1 (en) | Methods of Making and Using Nano Scale Particles | |
JP2003535030A (ja) | 保存リポソーム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN IN KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002255329 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1159/KOLNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2442151 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028073045 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002724742 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037013495 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10476083 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2002724742 Country of ref document: EP |